What a Skin Biopsy Actually Decides: Breslow Depth and Melanoma Staging

The number that sets the course

When a suspicious mole is removed and sent to pathology, the most consequential figure on the report is a single measurement in millimeters. It is called the Breslow thickness, and it records how deep melanoma cells have invaded the skin. That one number does more to predict outcome and steer the next step than almost anything visible to the eye. Under the American Joint Committee on Cancer (AJCC) 8th edition system, tumor thickness, together with whether the surface is ulcerated, defines the T category that anchors the entire stage, which is why the pathology report is the pivotal document.

How the depth is actually measured

Breslow thickness is measured under the microscope with a calibrated ocular micrometer, from the top of the granular layer of the epidermis (or the base of an ulcer, if the surface is broken) down to the deepest tumor cell. The 8th edition asks pathologists to record it to the nearest 0.1 mm rather than the nearest 0.01 mm, a change that Keung and Gershenwald describe as reflecting the real limits of measurement precision (Expert Rev Anticancer Ther, 2018). A reading of 0.75 mm rounds to 0.8; a reading of 0.74 rounds to 0.7. That rounding is not a technicality, because the 0.8 mm line now separates two different risk groups.

Thickness, ulceration, and the T categories

The T categories climb with depth. T1 covers melanomas up to 1.0 mm, T2 spans more than 1.0 up to 2.0 mm, T3 more than 2.0 up to 4.0 mm, and T4 anything thicker than 4.0 mm. Within each band, the letter a or b is assigned largely by ulceration, the microscopic finding that the epidermis over the tumor has broken down. Ulceration marks a worse outlook at every thickness, which is why an ulcerated tumor is generally shifted into the higher-risk b subcategory.

The most discussed revision in the 8th edition sits inside T1. As the definitive staging paper by Gershenwald and colleagues explains (CA: A Cancer Journal for Clinicians, 2017), a thin melanoma qualifies as T1a only if it measures under 0.8 mm and is not ulcerated. A tumor measuring 0.8 to 1.0 mm, or any ulcerated melanoma under 0.8 mm, becomes T1b. The reason is data rather than convention: patients in that 0.8 to 1.0 mm group carry higher melanoma-specific mortality and a greater chance of disease turning up in a sentinel lymph node, roughly 5 to 12 percent versus under 5 percent for the thinnest, non-ulcerated tumors.

Why mitotic rate changed roles

Here the report deserves careful reading, because a familiar criterion moved. In the 7th edition, a mitotic rate of at least one cell division per square millimeter could push a thin melanoma into the higher T1b subcategory. The 8th edition removed mitotic rate from the T1 definition after finding that thickness split at 0.8 mm predicted survival more reliably. This is not the same as saying mitotic rate stopped mattering. Gershenwald and colleagues still describe it as a strong independent predictor of outcome and recommend that it be documented, as a whole number per square millimeter, for every invasive melanoma. A modern report will therefore still list the mitotic count; it simply no longer changes the T1 letter on its own.

Clark level, the older anatomic measure of which skin layer the tumor reached, was likewise dropped from staging. Depth in millimeters proved more reproducible and more predictive than the layer-by-layer scheme it replaced.

Why the biopsy method matters

Because thickness is the hinge, how the lesion is sampled affects what can be concluded. A biopsy that removes the full lesion down through the fat allows the true deepest point to be measured. A superficial shave or a narrow punch through the middle of a pigmented lesion can transect the tumor and leave the real base unsampled, which risks underestimating Breslow thickness and, with it, the stage. This is why guidance favors sampling that captures the entire depth whenever melanoma is a serious consideration, and why an initial partial biopsy sometimes prompts a wider re-excision before the stage is finalized.

Reading the report as a whole

Stage is not thickness alone. The full AJCC framework combines the T category with N (whether regional nodes contain melanoma, often assessed by sentinel node biopsy) and M (distant spread). But the primary tumor's own line items, thickness first, then ulceration, then mitotic rate and margin status, are what set the initial trajectory: how wide the surgical margin should be, whether a sentinel node procedure is discussed, and how closely someone is monitored afterward. Independent validation work has broadly supported the 8th edition's ability to separate risk groups, while also noting that the thinnest tumors still account for a large share of eventual deaths, simply because thin melanomas are so common (see the accuracy analysis published in 2020).

For anyone holding such a report, the practical step is to read past the diagnosis to the measurements, and to ask how each figure was obtained. This article is educational and not a substitute for individualized medical advice.